Low concentrations of arsenic induce vascular endothelial growth factor and nitric oxide release and stimulate angiogenesis in vitro

Chemical Research in Toxicology

Volumn 16, Issue 4, 2003, Pages 460-468

  Kao, Ying Hsien ^a   Yu, Chia Li ^b   Chang, Louis W ^c   Yu, Hsin Su ^a,d  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC; BASIC FIBROBLAST GROWTH FACTOR; DRINKING WATER; HEMOGLOBIN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; SCAVENGER; VASCULOTROPIN; VON WILLEBRAND FACTOR;

ANGIOGENESIS; ANTIGEN EXPRESSION; ARTICLE; CELL ACTIVATION; CELL GROWTH; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; ENDOTHELIUM CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; METASTASIS; PERIPHERAL VASCULAR DISEASE; SIGNAL TRANSDUCTION; UMBILICAL VEIN; WATER CONTAMINATION;

ARSENITES; CELL DIVISION; CELLS, CULTURED; ENDOTHELIAL CELLS; ENVIRONMENTAL POLLUTANTS; FLOW CYTOMETRY; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; NITRIC OXIDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SODIUM COMPOUNDS; TIME FACTORS; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 0037397116     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx025652a     Document Type: Article

References (62)

1. Tchounwou, P. B., Wilson, B., and Ishague, A. (1999) Important considerations in the development of public health advisories for arsenic and arsenic-containing compounds in drinking water. Rev. Environ. Health 14, 211-229.
2. Pershagen, G. (1981) The carcinogenicity of arsenic. Environ. Health Perspect. 40, 93-100.
3. Chiou, H.-Y., Hsueh, Y.-M., Liaw, K.-F., Horng, S.-F., Chiang, M.-H., Pu, Y.-S., Lin, J.-S., Huang, C.-H., and Chen, C.-J. (1995) Incidence of internal cancers and ingested inorganic arsenic: a seven-year-follow-up study in Taiwan. Cancer Res. 55, 1296-1300.
4. Tsai, S.-M., Wang, T.-N., and Ko, Y.-C. (1998) Cancer mortality trends in a blackfoot disease endemic community of Taiwan following water source replacement. J. Toxicol. Environ. Health, Part A 55, 389-404.
5. Chen, C.-J., and Lin, L.-J. (1994) Human carcinogenicity and atherogenicity induced by chronic exposure to inorganic arsenic. In Arsenic in the Environment, Part 11: Human Health and Ecosystem Effects (Nriagu, J. O., Ed.) pp 109-131, John Wiley & Sons, New York.
6. Engel, R. R., Hopenhayn-Rich, C., Receveur, O., and Smith, A. H. (1994) Vascular effects of chronic arsenic exposure: a review. Epidemiol. Rev. 16, 184-209.
7. Engel, R. R., and Smith, A. H. (1994) Arsenic in drinking water and mortality from vascular disease: an exologic analysis in 30 counties in the United States. Arch. Environ. Health 49, 418-427.
8. Tseng, W.-P., Chu, H.-M., How, S.-W., Fong, J.-M., Lin, C.-S., and Yeh, S. (1968) Prevalence of skin cancer in an endemic area of chronic arsenicism in Taiwan. J. Natl. Cancer Inst. 40, 453-463.
9. Yu, H.-S. (1984) Blackfoot disease and chronic arsenism in southern Taiwan. Int. J. Dermatol. 23, 258-260.
10. Barchowsky, A., Roussel, R. R., Klei, L. R., James, P. E., Ganju, N., Smith, K. R., and Dudek, E. J. (1999) Low levels of arsenic trioxide stimulate proliferative signals in primary vascular cells without activating stress effector pathways. Toxicol. Appl. Pharmacol. 159, 65-75.
11. Roboz, G. J., Dias, S., Lam, G., Lane, W. J., Soignet, S. L., Warrell, R. P., Jr., and Rafii, S. (2000) Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood 96, 1525-1530.
12. Tomanek, R. J., and Schatteman, G. C. (2000) Angiogenesis: new insights and therapeutic potential. Anat. Rec. 261, 126-135.
13. Ferrara, N., Houck, K., Jakeman, L., and Leung, D. W. (1992) Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocrinol. Rev. 13, 18-32.
14. Ferrara, N. (1996) Vascular endothelial growth factor. Eur. J. Cancer 32A, 2413-2422.
15. Brown, L. F., Detmar, M., Claffey, K., Nagy, J. A., Feng, D., Dvorak, A. M., and Dvorak, H. F. (1997) Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS 79, 233-269.
16. Thomas, K. A. (1996) Vascular endothelial growth factor, a potent selective angiogenic agent. J. Biol. Chem. 271, 603-606.
17. Furchgott, R. F., and Zawadzki, J. V. (1980) The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288, 373-376.
18. Kubes, P., Suzuki, M., and Granger, D. N. (1991) Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc. Natl. Acad. Sci. U.S.A. 88, 4651-4655.
19. Kubes, P., and Granger, D. N. (1992) Nitric oxide modulates microvascular permeability. Am. J. Physiol. 262, H611-H615.
20. Loscalzo, J., and Welch, G. (1995) Nitric oxide and its role in the cardiovascular system. Prog. Cardiovasc. Dis. 38, 87-104.
21. Papapetropoulos, A., Garcia-Cardena, G., Madri, J. A., and Sessa, W. C. (1997) Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J. Clin. Invest. 100, 3131-3139.
22. Ziche, M., Morbidelli, L., Masini, E., Amerini, S., Granger, H. J., Maggi, C. A, Geppetti, P., and Ledda, F. (1994) Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. J. Clin. Invest. 94, 2036-2044.
23. Ziche, M., Morbidelli, L., Choudhuri, R., Zhang, H.-T., Donnini, S., Granger, H. J., and Bicknell, R. (1997) Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not fibroblast growth factor-induced angiogenesis. J. Clin. Invest. 99, 2625-2634.
24. Jaffe, E. A., Nachman, R. L., Becher, C. G., and Minick, R. (1973) Culture of human endothelial cells derived from umbilical veins: identification by morphologic and immunologic criteria. J. Clin. Invest. 52, 1745-1756.
25. Scudiero, D. A., Shoemaker, R. H., Paull, K. D., Monks, A., Tierney, S., Nofziger, T. H., Currens, M. J., Seniff, D. D., and Boyd, M. R. (1988) Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res. 48, 4827-4833.
26. Mateo, A. O, and Artinano, M. A. A. (2000) Nitric oxide reactivity and mechanisms involved in its biological effects. Pharmacol. Res. 42, 421-427.
27. Iijima, K., Yoshikawa, N., Connolly, D. T., and Nakamura, H. (1993) Human mesangial cells and peripheral blood mononuclear cells produce vascular permeability factor. Kidney Int. 44, 959-966.
28. 15nitrate in biological fluids. Anal. Biochem. 126, 131-138.
29. Zanetta, L., Marcus, S. G., Vasile, J., Dobryansky, M., Cohen, H., Eng, K., Shamamian, P., and Mignatti, P. (2000) Expression of Von Willebrand factor, an endothelial cell marker, is upregulated by angiogenesis factors: a potential method for objective assessment of tumor angiogenesis. Int. J. Cancer 85, 281-288.
30. Rudel, R., Slayton, T. M., and Beck, B. D. (1996) Implications of arsenic genotoxicity for dose response of carcinogenic effects. Regul. Toxicol. Pharmacol. 23, 87-105.
31. Hartwig, A., Groblinghoff, U. D., Beyersmann, D., Natarajan, A. T., Filon, R., and Mullenders, L. H. (1997) Interaction of arsenic (III) with nucleotide excision repair in UV-irradiated human fibroblasts. Carcinogenesis 18, 2278-2283.
32. Trouba, K. J., Wauson, E. M., and Vorce, R. L. (2000) Sodium arsenite-induced dysregulation of proteins involved in proliferative signaling. Toxicol. Appl. Pharmacol. 164, 161-170.
33. Jha, A. N., Noditi, M., Nilsson, R., and Natarajan, A. T. (1992) Genotoxic effects of sodium arsenite on human cells. Mutat. Res. 284, 215-221.
34. Yager, J. W., and Wiencke, J. K. (1997) Inhibition of poly (ADP-ribose) polymerase by arsenite. Mutat. Res. 386, 345-351.
35. Streuli, C. (1999) Extracellular matrix remodelling and cellular differentiation. Curr. Opin. Cell Biol. 11, 634-640.
36. Terman, B. I., Vermazen, M. D., Carrion, M. E., Dimitrov, D., Armellino, D. C., Gospodarowicz, D., and Bohlen, P. (1992) Identification of the KDR tyrosine kinase as a receptor for vascular endothelial growth factor. Biochem. Biophys. Res. Commun. 34, 1578-1586.
37. Waltenberger, J., Claesson-Welsh, L., Siegbahn, A., Shibuya, M., and Heldin, C. H. (1994) Different signal transduction properties of KDR and Flt-1, two receptors for vascular endothelial growth factor. J. Biol. Chem. 269, 26988-26995.
38. Barleon, B., Welch, H. A., and Marme, D. (1994) Differential regulation of the two VEGF receptor genes flt-1 and kdr by cytokines and growth factors. J. Cell Biochem. 18A (Suppl.), 323.
39. He, H., Venema, V. J., Gu, X., Venema, R. C., Marrero, M. B., and Caldwell, R. B. (1999) Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src. J. Biol. Chem. 274, 25130-25135.
40. Kroll, J., and Waltenberger, J. (1999) A novel function of VEGF receptor-2 (KDR): rapid release of nitric oxide in response to VEGF-A stimulation in endothelial cells. Biochem. Biophys. Res. Commun. 265, 636-639.
41. van der Zee, R., Murohara, T., Luo, Z., Zollmann, F., Passeri, J., Lekutat, C., and Isner, J. M. (1997) Vascular endothelial growth factor/vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothelium. Circulation 95, 1030-1037.
42. Wu, H.-M., Huang, Q., Yuan, Y., and Granger, H. J. (1996) VEGF induces NO-dependent hyperpermeability in coronary venules. Am. J. Physiol. 271, H2735-H2739.
43. Murohara, T., Horowitz, J. R., Silver, M., Tsurumi, Y., Chen, D., Sullivan, A., and Isner, J. M. (1998) Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation 97, 99-107.
44. Hood, J. D., Meininger, C. J., Ziche, M., and Granger, H. J. (1998) VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am. J. Physiol. 274, H1054-H1058.
45. Morbidelli, L., Chang, C.-H., Douglas, J. G., Granger, H. J., Ledda, F., and Ziche, M. (1996) Nitric oxide mediates mitogenic effect of VEGF on coronary venular endothelium. Am. J. Physiol. 270, H411-H415.
46. Murohara, T., Asahara, T., Silver, M., Bauters, C., Masuda, H., Kalka, C., Kearney, M., Chen, D. H., Chen, D. F., Symes, J. F., Fishman, M. C., and Huang, P. (1998) Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J. Clin. Invest. 101, 2567-2578.
47. Tuder, R. M., Flook, B. E., and Voelkel, N. F. (1995) Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide. J. Clin. Invest. 95, 1798-1807.
48. Fischer, S., Clauss, M., Wiesnet, M., Renz, D., Schaper, W., and Karliczek, G. F. (1999) Hypoxia induces permeability in brain microvessel endothelial cells via VEGF and NO. Am. J. Physiol. 276, C812-C820.
49. Tsurumi, Y., Murohara, T., Krasinski, K., Chen, D., Witzenbichler, B., Kearney, M., Couffinhal, T., and Isner, J. M. (1997) Reciprocal relation between VEGF and NO in the regulation of endothelial integrity. Nat. Med. 3, 879-886.
50. Shizukuda, Y., Tang, S., Yokota, R., and Ware, J. A. (1999) Vascular endothelial growth factor-induced endothelial cell migration and proliferation depend on a nitric oxide-mediated decrease in protein kinase Cdelta activity. Circ. Res. 85, 247-256.
51. Radisavljevic, Z., Avraham, H., and Avraham, S. (2000) Vascular endothelial growth factor up-regulates ICAM-1 expression via the phosphatidylinositol 3 OH-kinase/AKT/Nitric oxide pathway and modulates migration of brain microvascular endothelial cells. J. Biol. Chem. 275, 20770-20774.
52. Houck, K. A., Leung, D. W., Rowland, A. M., Winer, J., and Ferrara, N. (1992) Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J. Biol. Chem. 267, 26031-26037.
53. Bredt, D. S., and Snyder, S. H. (1990) Isolation of nitric oxide synthase, a calmodulin-requiring enzyme. Proc. Natl. Acad. Sci. U.S.A. 87, 682-685.
54. Busse, R., and Mulsch, A. (1990) Calcium-dependent nitric oxide synthesis in endothelial cytosol is mediated by calmodulin. FEBS Lett. 265, 133-136.
55. Cho, H.-J., Xie, Q.-W., Calaycay, J., Mumford, R. A., Swiderek, K. M., Lee, T.-D., and Nathan, C. (1992) Calmodulin is a subunit of nitric oxide synthase from macrophages. J. Exp. Med. 176, 599-604.
56. Nathan, C. (1992) Nitric oxide as a secretory product for mammalian cells. FASEB J. 6, 3051-3064.
57. Barchowsky, A., Klei, L. R., Dudek, E. J., Swartz, H. M., and James, P. E. (1999) Stimulation of reactive oxygen, but not reactive nitrogen species, in vascular endothelial cells exposed to low levels of arsenite. Free Radical Biol. Med. 27, 1405-1412.
58. Regelson, W., Kim, U., Ospina, J., and Holland, J. F. (1968) Hemangioendothelial sarcoma of liver from chronic arsenic intoxication by Fowler's solution. Cancer 21, 514-522.
59. Lander, J. J., Stanley, R. J., Sumner, H. W., Boswell, D. C., and Aach, R. D. (1975) Angiosarcoma of the liver associated with Fowler's solution (potassium arsenite). Gastroenterology 68, 1582-1586.
60. Falk, H., Caldwell, G. G., Ishak, K. G., Thomas, L. B., and Popper, H. (1981) Arsenic-related hepatic angiosarcoma. Am. J. Ind. Med. 2, 43-50.
61. Zaldivar, R., Prunes, L., and Ghai, G. L. (1981) Arsenic dose in patients with cutaneous carcinoma and hepatic hemangioendothelioma after environmental and occupational exposure. Arch. Toxicol. 47, 145-154.
62. Tsai, S. H., Hsieh, M. S., Chen, L., Liang, Y. C., Lin, J. K., and Lin, S. Y. (2001) Suppression of Fas ligand expression on endothelial cells by arsenite through reactive oxygen species. Toxicol. Lett. 123, 11-19.